CagriSema & Cagrilintide in 2026: REDEFINE Trial Data, Amylin Mechanism & GLP-1 Comparisons

CagriSema (cagrilintide + semaglutide) posted 20.4% mean weight loss in REDEFINE 1 and strong glycemic data in REIMAGINE. Full trial breakdown, amycretin outlook, and comparisons to tirzepatide and retatrutide.